Table 2 Age at appearance of signs and start of different treatments
From: Meglitinide (repaglinide) therapy in permanent neonatal diabetes mellitus: two case reports
Patients | Age | Age at appearance of signs and start of different treatments |
|---|---|---|
Case # 1 N.NE | 47 days | Signs appeared |
52 days | Came to hospital with DKA; treatment: low-dose insulin infusion, fluid therapy, then maintenance insulin therapy | |
58 days | Glibenclamide | |
2.4 years | Repaglinide | |
10 years | Repaglinide; no adverse events | |
Case # 2 I.M. | 3 months and 5 days | Signs appeared |
3 months and 15 days | Came to hospital with DKA; low-dose insulin infusion, fluid therapy, then maintenance insulin therapy | |
3 months and 20 days | Glibenclamide | |
4 months and 20 days | Repaglinide | |
9 years | Repaglinide; no adverse events |